Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Zosteriform Primary Cutaneous Marginal Zone Lymphoma-A Case Report.

The Australasian journal of dermatology·2025

Same author

Australian experience and practical approach to the 308-nm excimer light therapy in dermatology.

The Australasian journal of dermatology·2022

Same author

Successful treatment of pityriasis rubra pilaris with tildrakizumab.

The Australasian journal of dermatology·2021

Same author

Dermatological presentations for a walk-in Skin Clinic in Fiji.

The Australasian journal of dermatology·2021

Same author

Vesiculobullous Hailey-Hailey's disease with scarring mimicking a subepidermal autoimmune blistering disease and its management with retinoids.

The Australasian journal of dermatology·2021

Same author

Challenges in diagnosing hydroxychloroquine myopathy during the COVID-19 pandemic.

Internal medicine journal·2020

Search research articles

Related Experiment Video

Updated: Dec 17, 2025

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Published on: January 19, 2024

Eosinophilic cellulitis successfully treated with Methotrexate.

Janice Yeon¹, Renee Cf Chan¹, Samuel Zagarella¹

¹Concord Repatriation General Hospital, Concord, NSW, Australia.

The Australasian Journal of Dermatology

|June 26, 2020

Summary

This summary is machine-generated.

Eosinophilic cellulitis, a rare skin condition, can be challenging to treat. Methotrexate offers a safe and effective alternative to long-term oral steroids for managing this inflammatory disease.

Keywords:

Well syndrome corticosteroids eosinophilic cellulitis flame figures methotrexate

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Related Experiment Videos

Last Updated: Dec 17, 2025

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Published on: January 19, 2024

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Area of Science:

Dermatology
Immunology
Inflammatory Skin Diseases

Background:

Eosinophilic cellulitis is a rare, idiopathic inflammatory skin condition.
Characterized by recurrent, pruritic plaques, vesicles, or bullae, often on extremities and trunk.
Traditional treatments involve prolonged oral steroids, leading to potential side effects.

Observation:

This report details a case of eosinophilic cellulitis.
The patient's condition was managed using methotrexate.
Methotrexate was administered as a therapeutic intervention.

Findings:

Methotrexate demonstrated safety and efficacy in treating eosinophilic cellulitis.
This suggests methotrexate as a viable alternative to oral steroids.
The study contributes to understanding treatment options for this rare disease.

Implications:

Methotrexate presents a promising alternative for eosinophilic cellulitis management.
Reducing reliance on long-term corticosteroid therapy.
Potential for improved patient outcomes and reduced treatment-related adverse events.